A pan-influenza drug is widely sought in order to enable treating infections from novel influenza viruses. It is well known that pandemics can be caused by novel strains of influenza. Fortunately the current swine flu H1N1/2009 pandemic is now believed to cause fatality rates comparable to seasonal influenzas. However, influenza viruses are known to change rapidly. New influenza viruses are often generated by mixing of genetic material from existing influenza viruses, known as reassortments. Such changes can lead to a novel virus that is capable of causing a wide-spread pandemic accompanied by a high fatality rate. In addition, mutations are known to have led to influenza strains resistant to existing anti-influenza drugs. The Company believes that FluCide is designed to minimize the possibility of resistant mutations.

All of the Company ™s anti-influenza studies to date have been conducted by independent external investigators.

Dr. Seymour will join other industry panelists in the Evolving Role of Anti-Virals session to discuss drug resistance, drug efficacy and clinical development of anti-viral treatments for influenza. The panelists and participants include pharmaceutical and biotech decision makers and executives as well as government and regulatory agency representatives from a number of countries.

This conference is designed to bring together key stakeholders from the pharmaceutical and biotech industries, as well as governmental science and regulatory segments to discuss appropriate responses to the evolving influenza pandemic, according to the organizers.

SOURCE NanoViricides, Inc.